Program

Opening Remarks
Keynote Speaker
Schedule: Day One
Schedule: Day Two
Poster Presentations
Session Chair & Speaker Bios
Opening Remarks

Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior & Health

Stephen T. Higgins, Ph.D., is Director of the University of Vermont’s (UVM) Center on Behavior and Health, and Principle Investigator on five NIH grants on the general topic of behavior and health, namely the Vermont Center on Tobacco Regulatory Science and the Center of Biomedical Research Excellence, as well as two research grants and an institutional training award. He is the Virginia H. Donaldson Endowed Professor of Translational Science in the Departments of Psychiatry and Psychological Science and serves as Vice Chair of Psychiatry. He has held many national scientific leadership positions, including terms as President of the College on Problems of Drug Dependence and the American Psychological Association’s Division on Psychopharmacology and Substance Abuse. He is the author of more than 300 journal articles and invited book chapters and editor of a dozen volumes and therapist manuals in the area of behavior and health.

Video Welcome Message

The Honorable Patrick J. Leahy
United States Senator from Vermont

The conference kicks off with a special video message of appreciation and support from U.S. Senator Patrick Leahy of Vermont. Leahy is the Ranking Member of the Senate Judiciary Committee. He is the senior-most member of the Appropriations Committee and of the Agriculture Committee. Leahy is the Ranking Member of the Appropriations Subcommittee on State Department, Foreign Operations and Related Programs. He ranks first in seniority in the Senate.
Keynote Address

“FDA’s New Comprehensive Plan for Nicotine Regulation”

Mitch Zeller, J.D.
*Director, U.S. Food and Drug Administration’s Center for Tobacco Products*

Mitch Zeller, J.D., became director of the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) in March 2013. The mission of CTP—established by enactment of the 2009 Family Smoking Prevention and Tobacco Control Act—is “to make tobacco-related death and disease part of America's past, not America's future, and, by doing so, ensure a healthier life for every American family.”

Mr. Zeller, a graduate of Dartmouth College and the American University Washington College of Law, has been working on FDA issues for more than 30 years. He began his career as a public interest attorney in 1982 at the Center for Science in the Public Interest (CSPI). In 1988, Mr. Zeller left CSPI to become counsel to the Human Resources and Intergovernmental Relations Subcommittee of the House of Representatives Government Operations Committee where he conducted oversight of enforcement of federal health and safety laws.

Mr. Zeller joined the staff of then FDA Commissioner David Kessler, M.D., in 1993. What began as a two-week assignment by Kessler to examine the practices of the tobacco industry led to his serving as associate commissioner and director of FDA’s first Office of Tobacco Programs. Instrumental in crafting the agency’s 1996 tobacco regulations, Mr. Zeller also represented FDA before Congress, federal, and state agencies. Mr. Zeller also served as an official U.S. delegate to the World Health Organization Working Group for the Framework Convention on Tobacco Control.
Thursday, October 5: Adirondack AB & CD

7:15-8:00 BREAKFAST & REGISTRATION

8:05-8:25 Opening Remarks: Stephen T. Higgins, Ph.D., Director
    Video Welcome: U.S. Senator Patrick J. Leahy of Vermont

Keynote Address: FDA’s New Comprehensive Plan for Nicotine Regulation

8:30-9:25 Delivered by Mitch Zeller, J.D., Director, U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP)

Session Chair: Stephen T. Higgins, Ph.D., Director, University of Vermont (UVM) Tobacco Center of Regulatory Science; Virginia H. Donaldson Professor in Translational Science, Departments of Psychiatry and Psychological Science, UVM

9:30-9:40 COFFEE BREAK

Panel on Very Low Nicotine Content Cigarettes

Session Chairs: Neal Benowitz, M.D., Core Director and Investigator, University of California, San Francisco (UCSF) Tobacco Center of Regulatory Science; Professor of Medicine and Bioengineering & Therapeutic Sciences, UCSF and Jack E. Henningfield, Ph.D., Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates; Professor of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine

9:45-10:10 Approaches to Reducing Nicotine in Cigarettes Dorothy K. Hatsukami, Ph.D., Co-Director, Center for the Evaluation of Nicotine in Cigarettes; Forster Family Chair in Cancer Prevention and Associate Director, Cancer Prevention and Control, University of Minnesota Masonic Cancer Center; Professor of Psychiatry and Director of the Tobacco Research Programs, University of Minnesota

10:15-10:40 Main Effects and Moderators of the Impact of Nicotine Content on Smoking Rate and Nicotine Dependence Eric C. Donny, Ph.D., Co-Director, Center for the Evaluation of Nicotine in Cigarettes; Professor of Physiology & Pharmacology, Baptist Cancer Center, Wake Forest

10:45-11:10 Nicotine Content and Addiction Potential of Cigarettes in Vulnerable Populations Stephen T. Higgins, Ph.D., Director, UVM Tobacco Center of Regulatory Science; Virginia H. Donaldson Professor of Translational Science in Psychiatry and Psychological Science, UVM

11:15-11:40 Reduced Nicotine Content Cigarettes in Vulnerable Populations: How Might our Research be Challenged? Jonathan Foulds, Ph.D., Principal Investigator, Penn State Tobacco
Center of Regulatory Science; Professor of Public Health Sciences and Psychiatry, Penn State College of Medicine

11:45-12:10 **PANEL DISCUSSION**

12:15-1:25 **LUNCH** (Boxed Lunches Available*)

12:25-1:20 **SPECIAL EVENT: NIH and FDA FUNDING OPPORTUNITIES FOR EARLY CAREER INVESTIGATORS** *We invite session attendees to bring their boxed lunches.* Samia D. Nouri, Ph.D., Program Official, Services Branch, Division of Epidemiology, Services & Prevention Research, National Institute on Drug Abuse (NIDA); and Megan J. Schroeder, Ph.D., Lead Pharmacologist, Division of Individual Health Science/Office of Science, FDA CTP

**Panel on Tobacco Regulatory Science and Vulnerable Populations**

**Session Chair:** Diann E. Gaalema, Ph.D., Project Site Principal Investigator, UVM Tobacco Center of Regulatory Science; Research Assistant Professor, Departments of Psychiatry and Psychological Science, UVM

1:30-1:55 **A Latent Class Analysis of Tobacco Harm Perceptions Among Nationally Representative U.S. Youth** Grace Kong, Ph.D., Investigator, Yale Tobacco Center of Regulatory Science; Assistant Professor of Psychiatry, Yale School of Medicine

2:00-2:25 **Co-occurring Vulnerabilities in Young Adult Smokers** Andrea C. Villanti, Ph.D., M.P.H., Associate Director, UVM Tobacco Center of Regulatory Science; Research Associate Professor of Psychiatry, UVM

2:30-2:55 **Smoking Among Women of Reproductive Age** Sarah H. Heil, Ph.D., Project Principal Investigator, UVM Tobacco Center of Regulatory Science; Associate Professor of Psychiatry and Psychological Science, UVM

3:00-3:25 **Effects of Reduced Nicotine Content Cigarettes in Smokers with Mental Health Conditions** Jennifer W. Tidey, Ph.D., Project Principal Investigator, UVM Tobacco Center of Regulatory Science and Center for the Evaluation of Nicotine in Cigarettes; Professor of Psychiatry & Human Behavior and Behavioral & Social Sciences, Brown University

3:30-3:55 **Smoking Among Opioid-Dependent Individuals: Nicotine Reinforcement, Withdrawal, and Response to Interventions** Stacey C. Sigmon, Ph.D., Project Principal Investigator, UVM Tobacco Center of Regulatory Science; Associate Professor of Psychiatry and Psychological Science, UVM

4:00-4:25 **PANEL DISCUSSION**
4:30-6:00 RECEPTION & POSTER SESSION: Prefunction & Montpelier Room

Friday, October 6: Adirondack AB & CD

7:15-8:10 BREAKFAST

Panel on Challenges/Potential Benefits of Facilitating Substitution of Non-combustible Products for Conventional Cigarettes Among Persistent Cigarette Smokers

Co-Chairs: Jack E. Henningfield, Ph.D., Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates; Professor of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine and Stephen T. Higgins, Ph.D., Director, UVM Tobacco Center of Regulatory Science; Virginia H. Donaldson Professor in Translational Science, Departments of Psychiatry and Psychological Science, UVM

8:15-8:25 Opening remarks from the Chairs

8:30-8:55 Harm Minimization and Tobacco Control: Reframing Societal Views of Nicotine Use to Rapidly Save Lives David B. Abrams, Ph.D., Professor, NYU College of Global Public Health, New York University

9:00-9:25 Relative Health Risks of Conventional Cigarettes versus e-Cigarettes Neal Benowitz, M.D., Core Director and Investigator, UCSF Tobacco Center of Regulatory Science; Professor of Medicine and Bioengineering & Therapeutic Sciences, UCSF

9:30-9:40 COFFEE BREAK

9:45-10:10 Changing Perceptions of the Relative Harm of e-Cigarettes and Other Tobacco Products in the U.S. Population Michael Eriksen, Sc.D., Director, Georgia State University Tobacco Center of Regulatory Science; Dean and Regents Professor, School of Public Health, Georgia State University

10:15-10:40 Relative Nicotine Dependence Risk of Conventional and Electronic Cigarettes John R. Hughes, M.D., Associate Director, UVM Tobacco Center of Regulatory Science; Professor, Departments of Psychiatry, Psychological Science, and Family Medicine, UVM

10:45-11:10 The Role of Economics in Determining Product Use Jidong Huang, Ph.D., Associate Professor, Division of Health Management and Policy, School of Public Health, Georgia State University

Behavioral Health Research Professorship; Director, Addiction Recovery Research Center; Professor of Psychiatry & Behavioral Medicine, Virginia Tech Carilion School of Medicine, and Psychology, Virginia Tech University

11:45-12:15 **LUNCH**

**Chairs:** John R. Hughes, M.D., Associate Director, UVM Tobacco Center of Regulatory Science; Professor, Departments of Psychiatry, Psychological Science, and Family Medicine, University of Vermont and Andrea C. Villanti, Ph.D., Associate Director, UVM Tobacco Center of Regulatory Science; Research Associate Professor of Psychiatry, UVM

12:20-12:45 **Use of e-Cigarettes Among Pregnant and Non-Pregnant Women of Reproductive Age** Allison N. Kurti, Ph.D., Investigator, UVM Tobacco Center of Regulatory Science; Research Assistant Professor of Psychiatry, UVM

12:50-1:15 **Electronic Cigarette Use Among Individuals with Mental Illness** Mollie E. Miller, Ph.D., Postdoctoral Research Associate, Center for Alcohol and Addiction Studies, Brown University

1:20-1:45 **Searching for Something Safer? Risk Perception and Use of E-Cigarettes Among Those who Have Had a Cardiac Event** Diann E. Gaalema, Ph.D., Project Site Principal Investigator, UVM Tobacco Center of Regulatory Science; Research Assistant Professor, Departments of Psychiatry and Psychological Science, UVM

1:50-2:15 **PANEL DISCUSSION ON POLICY/REGULATORY IMPLICATIONS**

2:20 **ADJOURN**
Poster Presentations: Tobacco Regulatory Science

1. Why a Ban on Flavored Cigars is Long Overdue, Maham Akbar, M.P.P., Truth Initiative

2. Cigarettes Aren’t the Only Threat to Our Youth: What We Need to Know About Cigars, Maham Akbar, M.P.P., Truth Initiative

3. Reduction in Cigarettes per day Prospectively Predicts Making a Quit Attempt: A Fine-grained Secondary Analysis of a Natural History Study, Eli Klemperer, Ph.D. Candidate, Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

4. “If You Are Old Enough to Die for Your Country, You Should Be Able to Get a Pinch of Snuff”: View of Tobacco 21 Among Appalachian Youth, Lindsay Tompkins, Ph.D. Candidate, University of Louisville

5. Generally Recognized as Safe: Uncertainty Surrounding E-cigarette Flavoring Safety, Clara Sears, Ph.D., University of Louisville

6. Initial Laboratory Validation of E-cigarette Purchase Tasks in Advanced Generation E-Cigarette Users, Rachel Cassidy, Ph.D., and Victoria Long, Ph.D. Candidate, Brown University

7. Addressing Tobacco Use Among Adults with Mental Illness: Impact of an Integrated Primary Care Program in a Community Behavioral Health Clinic, Marc Budgazad, M.A., Family Health Centers at NYU Langone – Sunset Terrace

8. Impact of Question Type and Question Order on Tobacco Prevalence Estimates in U.S. Young Adults: A Randomized Experiment, Amanda Johnson, M.H.S., Schroeder Institute at Truth Initiative

9. Oxidative Stress Biomarkers While Smoking Usual Brand Cigarettes versus Usual Nicotine Content Research Cigarettes, Nicolle Krebs, M.S., Penn State University

10. Role of Propylene Glycol and Vegetable Glycerin Concentration on the Behavioral Effects of Electronic Cigarette Aerosol, Arit Harvanko, Ph.D. Candidate, University of Kentucky

11. The Influence of E-cigarette Use and Regulatory Environment on Cigarette Demand, Bryan Heckman, Ph.D., Medical University of South Carolina

12. E-cigarettes to Reduce Tobacco Smoking among Individuals with Serious Mental Illness, Jin Yoon, Ph.D., University of Texas Health Science Center at Austin

13. Disparities in the Prevalence and Importance of Tobacco Benefit and Harm Perceptions among U.S. Youth, Meghan Moran, Ph.D., Johns Hopkins Bloomberg School of Public Health
14. The Association of E-cigarette Use Motivations and Combustible Tobacco Use Over Time among Exclusive E-cigarette and Multiple Product Users, Amanda Quisenberry, Ph.D., Ohio State University

15. Smokers’ Misperceptions about Toxicity of Very Low Nicotine Cigarettes, Justin Byron, Ph.D., University of North Carolina

16. Brief Assessment of Cigarette Demand (BACD): Initial Development And Validation Results, Cara Murphy, Ph.D., Brown University

17. FDA Compliance Inspections on Retail Sales to Minors of Cigars and Electronic Cigarettes in the United States: 2016-2017, Hongying Dai, Ph.D., and Delwyn Catley, Ph.D., Children’s Mercy Kansas City

18. Impact of Flavorants and Sweeteners on Waterpipe Tobacco Smoking, Elly Leavens, M.S., Oklahoma Tobacco Research Center

19. Effect of Alcohol Consumption on Waterpipe Tobacco Smoking Patterns, Toxicant Exposure, and Smoking Experience, Elly Leavens, M.S., Oklahoma Tobacco Research Center

20. Associations between Opioid and Nicotine Dependence in Nationally Representative Samples of United States Adult Daily Smokers, Maria Parker, Ph.D., Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

21. Characterizing Nicotine Withdrawal Across Vulnerable Populations: Data from a Trial Examining Reduced Nicotine Content Cigarettes, Joanna Streck, Ph.D. Candidate, UVM Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

22. Examining Interrelationships between Delay Discounting and Simulated Demand for Cigarettes Among Pregnant Women, Tyler Nighbor, Ph.D., Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

23. Characterizing Responses to Cigarettes with Varying Levels of Nicotine in Women Vulnerable to Smoking During Pregnancy, Cecilia Bergeria, Ph.D. Candidate, Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

24. It’s a Trap! An Examination of Waterpipe Smokers and Non-Smokers’ Reactions to Anti-Waterpipe PSAs, Elise Stevens, Ph.D., University of Oklahoma Health Sciences Center

25. Persistence and Amplitude of Tobacco Demand among Cigarette Smokers with Clinical Depression: An Experimental Comparison with Non-depressed, Alba González de la Roz, Ph.D. Candidate, University of Oviedo
26. Characterization of Subjective, Physiological, and Behavioral Responses among Experienced E-cigarette Users, Irene Pericot-Valverde, Ph.D., Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

27. Examining the Influence on Mentholation on Relative Reinforcing Efficacy of Cigarettes in Varying Nicotine Doses, Danielle Davis, Ph.D. Candidate, Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

28. Household Smoking Rules: Effects on Nicotine Exposure and Birth Outcomes among Pregnant Women, Diana Keith, Ph.D., Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

29. Smoking Abstinence Among Patients with COPD: A Novel Extension of Evidence-based Treatment. Taylor Ochalek, Ph.D. Candidate, Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont

30. Examining the Ability of Purchase Tasks in Distinguishing Risky Populations of Substance Users, Ivori Zvorsky, Ph.D. Candidate, Tobacco Center of Regulatory Science, Vermont Center on Behavior and Health, University of Vermont
**Session Chair & Speaker Bios** *(in alphabetical order)*

**David Abrams, Ph.D.**
Dr. Abrams holds a B.Sc. (Hons.) in Psychology and Computer Science, University of the Witwatersrand, South Africa and a Doctorate, Health Psychology, Rutgers University, United States. He was Professor and founding Director of the Centers for Behavioral and Preventive Medicine, Brown University. He directed the Office of Behavioral and Social Sciences Research (OBSSR), National Institutes of Health. He has published over 270 peer reviewed articles, is Principal Investigator on numerous NIH grants and served on the Board of Scientific Advisors of the National Cancer Institute. He was President of the Society for Behavioral Medicine and recipient of their Distinguished Scientist, Research Mentorship and Service Awards; received the Cullen Memorial Award, American Society for Preventive Oncology for lifetime contributions to tobacco control; Research Laureate Award, American Academy of Health Behavior; and the Distinguished Alumni Award, Rutgers University. He authored *The Tobacco Dependence Treatment Handbook: A Guide to Best Practices*, which won the *American Journal of Nursing* Book of the Year Award. Dr. Abram’s current focus is general health promotion in populations and nicotine use research from basic science to practice to policy. Science-informed practice, policy and regulation requires a re-framing of nicotine use in society to optimize net public health benefit of emerging disruptive technologies for alternative nicotine delivery and their harm minimization potential. The goal is to speed elimination of preventable deaths, disease burdens and excess costs caused overwhelmingly by lethal smoke from combusting tobacco, primarily cigarettes, not from nicotine. If more is not done now, smoked tobacco will prematurely kill over 1 billion smokers globally in the 21st century.

**Neal Benowitz, M.D.**
Dr. Benowitz is Professor of Medicine and Bioengineering & Therapeutic Sciences, and Chief of the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco (UCSF). He received his medical degree from the University of Rochester School of Medicine in 1969, following, which he served as a resident in internal medicine at the Bronx Municipal Hospital Center from 1969 to 1971. He then completed a postdoctoral fellowship in clinical pharmacology at UCSF and joined the faculty in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 600 research papers. Dr. Benowitz also maintains an active clinical practice in cardiovascular medicine and medical toxicology. Dr. Benowitz was a scientific editor of the 1988 U.S. Surgeon General’s report; a scientific editor of the 2001 National Cancer Institute Monograph; and served as section editor for the 2010 Surgeon General’s report. He has served as a member of the National Institutes of Health Pharmacology Study Section and the U.S. Food and Drug Administration Nonprescription Drug and Tobacco Products Science Advisory Committees. He has served as President of the American Society for Clinical Pharmacology and Therapeutics and as President of the Society for Research on Nicotine and Tobacco. Dr. Benowitz has received the Ove Ferno, Alton Ochsner, and Rawls-Palmer Progress in Medicine awards, and the Oscar B. Hunter Memorial Award in Therapeutics for his research on nicotine, tobacco, and health, and was the 2002 UCSF Annual Distinguished Clinical Research Lecturer.
Warren Bickel, Ph.D.
Dr. Bickel joined the Virginia Tech Carilion Research Institute in 2011 and serves as Director of the Addiction Recovery Research Center and Co-Director of the Center for Transformative Research on Health Behaviors. In recognition of his extraordinary contributions to research and scholarship achievements, Dr. Bickel was recently awarded the Virginia Tech Carilion Behavioral Health Research Endowed Professorship. He received his Ph.D. in developmental and child psychology from the University of Kansas and completed post doctoral training at Johns Hopkins University School of Medicine. He has taught and led research programs at the Albert Einstein College of Medicine, the University of Vermont, and the University of Arkansas for Medical Sciences. NIH has funded Dr. Bickel’s work continuously since 1987. Dr. Bickel is an accomplished scholar and researcher whose accolades include receipt of the 2011 American Psychological Association (APA) International Don Hake Translational Research Distinguished Contributions to Basic Research Award and the 2012 Brady-Schuster Award for Outstanding Behavioral Science Research in Psychopharmacology and Substance Abuse, Division 28 of APA. Dr. Bickel was honored to be the recipient of the 2016 Nathan B. Eddy Award from the College on Problems of Drug Dependence. He has served as President of the College on Problems of Drug Dependence, President of APA Division 28, and President of APA Division 50. Dr. Bickel was Editor of the journal, Experimental and Clinical Psychopharmacology, has co-edited five books, and has published over 350 papers and chapters. Dr. Bickel’s work is frequently cited and receives national and international recognition.

Eric Donny, Ph.D.
Dr. Donny is Professor of Physiology and Pharmacology and Public Health Science at Wake Forest University School of Medicine. His expertise includes behavioral pharmacology, biological and health psychology, addiction, and regulatory science. His research has included a wide range of topics and techniques including animal models of self-administration, human abuse liability, functional neuroimaging, population-based surveys, and clinical trials of tobacco products. His current interests focus on regulatory approaches to reducing the health burden of tobacco. He co-directs the Center for the Evaluation of Nicotine in Cigarettes (CENIC), a National Institute on Drug Abuse/U.S. Food and Drug Administration-funded cooperative agreement that aims to increase understanding of how behavior and health might be affected in the vast majority of smokers who are either unable or unwilling to quit, if the nicotine content of combustible tobacco products is reduced.

Michael Eriksen, Sc.D.
Dr. Eriksen is Regents’ Professor and founding Dean of the School of Public Health at Georgia State University. He is also director of Georgia State University’s Tobacco Center of Regulatory Science and the Center of Excellence in Health Disparities Research. Prior to his current positions, Dr. Eriksen served as a senior advisor to the World Health Organization in Geneva and was the longest-serving director of the Centers for Disease Control and Prevention’s (CDC) Office on Smoking and Health (1992-2000). Previously, Dr. Eriksen was director of behavioral research at the M.D. Anderson Cancer Center. He has recently served as an advisor to the Bill and Melinda Gates Foundation, the Robert Wood Johnson Foundation, the American Legacy Foundation, and the CDC Foundation. Dr. Eriksen has published extensively on tobacco prevention and control and is the lead author of The Tobacco Atlas. He has
served as an expert witness on behalf of the U.S. Department of Justice and the Federal Trade Commission in litigation against the tobacco industry. He is Editor-in-Chief of *Health Education Research* and has been designated as a Distinguished Cancer Scholar by the Georgia Cancer Coalition. He is a recipient of the World Health Organization Commemorative Medal on Tobacco or Health and a Presidential Citation for Meritorious Service, awarded by President Bill Clinton. Dr. Eriksen is a past president and Distinguished Fellow of the Society for Public Health Education, and has been a member of the American Public Health Association for over 40 years.

**Jonathan Foulds, Ph.D.**

Dr. Foulds is Professor of Public Health Sciences and Psychiatry at Penn State University, College of Medicine. After obtaining a first class honors degree in psychology at University of Aberdeen in Scotland, he trained as a clinical psychologist at the University of Glasgow, and then spent most of his career developing and evaluating methods to help smokers beat their addiction to tobacco. He obtained his Ph.D. at the Institute of Psychiatry, University of London and worked at St George’s Hospital Medical School as the UK’s first “lecturer in tobacco addiction”. He then moved to University of Surrey and continued to work as a principal clinical psychologist at Broadmoor Hospital, a large maximum security facility for mentally disordered offenders. He was on the Management Group of the Hungarian Anti-Smoking Campaign (1995-1996), has been a technical leader of a World Health Organization project to improve the regulation of tobacco dependence treatment in Europe (2000), and was Director of Research for the UK charity, Quit, which ran the largest telephone helpline for smokers in the world at that time. From 2000-2010 he was the director of the Tobacco Dependence Program (TDP) at the University of Medicine & Dentistry of New Jersey (now Rutgers)—School of Public Health. He was a founding member and Vice President of the Association for the Treatment of Tobacco Use and Dependence from 2004-2006. In the U.S., he has been a principal investigator on grants totaling well over $27 million, and has been invited to speak on smoking cessation in over 15 countries. He has published over 100 papers on tobacco in peer-reviewed scientific journals and continues to treat addicted smokers, teach on smoking cessation and conduct research on tobacco and health at Penn State College of Medicine in Hershey, PA.

**Diann Gaalema, Ph.D.**

Dr. Gaalema is Research Assistant Professor of Psychiatry and Psychological Science at the University of Vermont. She received her Ph.D. in Experimental Psychology from the Georgia Institute of Technology. Diann has a long-standing interest in behavioral science and has focused her career on measuring and changing a variety of behaviors. Her current research interests include motivating health-related behavior change and the use of tobacco in vulnerable populations such as those with chronic medical conditions. Currently she is the PI on a NIH funded project aimed at increasing cardiac rehabilitation participation among low income patients and is the site-PI on a National Institute on Drug Abuse/U.S. Food and Drug Administration-funded project examining the effects of cigarettes of varying nicotine levels on behavior in those with depression or anxiety disorders.
**Dorothy Hatsukami, Ph.D.**

Dr. Hatsukami is the Forster Family Chair in Cancer Prevention and Associate Director of Cancer Prevention and Control at the Masonic Cancer Center of the University of Minnesota, where she is also Professor of Psychiatry and Director of the Tobacco Research Programs. Her areas of expertise include nicotine addiction and its treatment, including testing medications such as a nicotine vaccine and combination medications, in smokers. She has over 400 publications and is currently PI/Co-PI of two large National Institutes of Health-funded cooperative agreements that involve assessing the toxicity, appeal and addictiveness of various tobacco products. She has served on numerous scientific advisory boards for the U.S. government including the 1) Food and Drug Administration, Tobacco Product Scientific Advisory Committee, 2) National Advisory Council on Drug Abuse, 3) Interagency Committee on Smoking and Health, 4) Substance Abuse and Mental Health Services Administration, 5) Scientific Board of Counselors for the National Institutes on Drug Abuse, and 6) the Drug Control Research, Data and Evaluation Committee of the Office on National Drug Control Policy. She is currently a member of the World Health Organization Study Group on Tobacco Product Regulation.

**Sarah Heil, Ph.D.**

Dr. Heil is Associate Professor of Psychiatry and Psychological Science at the University of Vermont and a faculty member of the Vermont Center on Behavior and Health. Dr. Heil earned her Ph.D. from Dartmouth College in 1997, then completed National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse (NIDA) postdoctoral fellowships in substance abuse research at Wayne State University and the University of Vermont. She joined the faculty at Vermont in 2002. Continuously funded by NIDA since that time, her research interests include the behavioral and pharmacological processes involved in substance use disorders, with a special focus on pregnant and recently postpartum women and their infants. Dr. Heil has more than 120 publications to her credit and is an elected Fellow of two divisions of the American Psychological Association. She is currently on the board of directors of the College on Problems of Drug Dependence and the editorial board of the journal Psychology of Addictive Behaviors.

**Jack Henningfield, Ph.D.**

Dr. Henningfield is Vice President of Research, Health Policy, and Abuse Liability at Pinney Associates and Adjunct Professor of Behavioral Biology in the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine, where he has been faculty since 1978. He is a past president of the Society for Research on Nicotine and Tobacco. He served on the U.S. Food and Drug Administration’s (FDA) first Tobacco Products Scientific Advisory Committee and the World Health Organization’s first Study Group on Tobacco Product Regulation and its predecessor, from 2000 to 2014. Before joining Pinney Associates, Dr. Henningfield headed clinical pharmacology and the Abuse Potential Assessment Laboratory of the National Institute on Drug Abuse where he advised FDA on controlled substance issues. He was an editor of the 1988 Surgeon General’s report on nicotine addiction, and contributed to many other reports including the 50th anniversary 2014 Surgeon General’s report. He has researched the neuropharmacology of alcohol, cannabis, opioids, nicotine, sedatives and stimulants, and many medicines for treating pain and psychiatric disorders, resulting in more than 400 scientific articles,
books and monographs. At Pinney Associates his focus is the assessment and regulation of drugs and drug-delivery systems to reduce their abuse and harmful effects.

**Jidong Huang, Ph.D.**

Dr. Huang is Associate Professor of Health Management and Policy and a Second Century Initiative (2CI) scholar in the Tobacco Center of Regulatory Science at the School of Public Health at Georgia State University. He was a contributing author to the 2016 Surgeon General’s report, and a contributing author to the 2017 National Cancer Institute’s/World Health Organization's monograph *Economics of Tobacco and Tobacco Control*. He has conducted extensive research assessing and evaluating the economic and public health impact of tobacco control policies and regulations, including tobacco prices/taxes, smoke free-air policies, tobacco control programs, graphic warning labels, point-of-sale advertising restrictions, point-of-sale display bans, minimum pricing laws, and other national- and state/local-level tobacco control policies or regulations. His current research involves examining the marketing and promotion of new and emerging tobacco products, particularly Electronic Nicotine Delivery Systems (ENDS), and how policies, regulations, and costs affect use of ENDS and other tobacco products. In addition, Dr. Huang has also conducted extensive research on the impact of tobacco control policies in reducing tobacco use in low- and middle-income countries.

**John Hughes, M.D.**

Dr. Hughes is Professor of Psychiatry, Psychology and Family Practice at the University of Vermont. Dr. Hughes is board certified in Psychiatry and Addiction Psychiatry. His major focus has been clinical research on tobacco use. He is a co-founder and past president of the Society for Research on Nicotine and Tobacco, and the Association for the Treatment of Tobacco Use and Dependence (ATTUD). Dr. Hughes received the Ove Ferno, Alton Ochsner and the John R. Hughes ATTUD Excellence in Tobacco Treatment, Training and Advocacy Award. Dr. Hughes has been Chair of the Vermont Tobacco Evaluation and Review Board, which oversees VT’s multi-million-dollar tobacco control program. He has over 450 publications on nicotine and other drug dependencies and is one of the world’s most cited tobacco scientist. Dr. Hughes has been a consultant on tobacco policy to the World Health Organization, the U.S. Food and Drug Administration, the U.S. Office on Smoking and Health and the White House. Dr. Hughes has received fees from companies who develop smoking cessation devices, medications and services, from governmental and academic institutions, and from public and private organizations that promote tobacco education or control and serves as a consultant to Swedish Match for their snus product.

**Grace Kong, Ph.D.**

Dr. Kong is Assistant Professor in the Department of Psychiatry at Yale School of Medicine. She received her Ph.D. in Clinical Psychology (Child and Adolescent Track) at St. John’s University in 2009, and completed her National Institute on Drug Abuse T32 postdoctoral fellowship focused on adolescent substance abuse in the Division of Substance Abuse at Yale School of Medicine in 2012. Dr. Kong’s current research interests include understanding substance use health disparities among youth, the use of social media for tobacco marketing, novel tobacco use behaviors among youth, and developing innovative adolescent tobacco/cessation interventions for youth.
**Allison N. Kurti, Ph.D.**

Dr. Kurti is Research Assistant Professor in the Department of Psychiatry at the University of Vermont (UVM). The overarching theme of Dr. Kurti’s research has been the development of innovative behavioral interventions to improve human health. Her current research focuses in particular on tobacco use in vulnerable populations, and can be broadly described as falling into one of two different categories: (1) developing and implementing behavioral smoking cessation treatments, and (2) tobacco regulatory science research intended to inform U.S. Food and Drug Administration tobacco product regulation. A majority of the research that Dr. Kurti conducted in both her doctoral program and in her postdoctoral fellowship was focused on the former, with the overarching goal in the domain of treatment being to design innovative (e.g., technology-based), efficacious behavioral interventions targeting high risk and underserved populations. As a new Center of Biomedical Research Excellence project director, Dr. Kurti is preparing to deliver a smartphone-based financial incentives intervention to promote smoking cessation among economically disadvantaged pregnant women. Because UVM is one of the fourteen P50 Tobacco Centers of Regulatory Science (TCORS), her postdoctoral fellowship and some of her current research has also involved collaborating with postdoctoral fellows and faculty from other TCORS institutions through her membership in a working group focused on tobacco use in vulnerable populations. Dr. Kurti has served as both lead author and co-author on a variety of manuscripts published by this working group, with her emphasis being on use of tobacco and nicotine delivery products among U.S. national samples of reproductive-aged women.

**Mollie Miller, Ph.D.**

Dr. Miller is an experimental psychologist trained in human behavioral psychopharmacology. Dr. Miller has conducted smoking research in vulnerable populations for the past 8 years. Her research investigates the mechanisms contributing to increased smoking rates among vulnerable populations, particularly adults with comorbid psychopathology or substance dependence, and evaluates novel behavioral and pharmacological interventions to promote sustained smoking cessation in these populations. Dr. Miller completed a Tobacco Centers of Regulatory Science-funded postdoctoral fellowship at Brown University’s Center for Alcohol and Addiction Studies in collaboration with the Vermont Center on Tobacco Regulatory Science, where she evaluated the effects of reduced-nicotine content cigarettes in smokers with co-morbid mental illness, reasons for alternative tobacco product use among those with mental illness, and the impact of socioeconomic status on tobacco switching behavior. Miller served as a member of the Vermont Tobacco Evaluation and Control Board, responsible for ensuring fiscal responsibility for state-funded tobacco control initiatives. She is a member of the Society for Research on Nicotine and Tobacco, the American Psychological Association Division 28, and an associate editor for Tobacco Regulatory Science.

**Samia D. Noursi, Ph.D.**

Dr. Noursi is a program official at the National Institute on Drug Abuse (NIDA), Division of Epidemiology, Services and Prevention Research, Services Research Branch. At NIDA, Dr. Noursi manages a portfolio of grants that focuses on treatment services including drug treatment court, smoking and tobacco, and women and HIV. Dr. Noursi received her Ph.D. in Applied Developmental Psychology from the University of Maryland in 1995. Upon graduation, she was awarded a Post-Doctoral fellowship at the Eunice
Kennedy Shriver National Institute on Child Health and Human Development during which she led a longitudinal study on the effects of domestic violence on children’s development. She then moved to work on several projects focused on children’s development among them directing research for the National Child Welfare Resource Center on Legal and Judicial Issues at the American Bar Association Center on Children and the Law. In 2006, Dr. Noursi joined NIDA as a Health Scientist Administrator and the Women and Sex/Gender Differences Research Deputy Coordinator where she assisted the NIDA’s Women and Sex/Gender Differences Research Coordinator in providing leadership for NIDA’s Women and Sex/Gender Differences Research Program. In addition, she served as Program Officer with a portfolio that focuses on sex/gender differences in the antecedents and consequences of drug abuse, study of vulnerability to drug abuse, and study of the behavioral effects of prenatal exposure to drugs. Dr. Noursi has presented numerous papers at national professional conferences and authored a number of articles in both peer-reviewed journals and books. She also served as the guest editor of the Journal on Women’s Health, 2015; 24(1). Intimate Partner Violence, Consequences on Women’s Health, and Promising Interventions and is currently a board member of the National Partnership to End Interpersonal Violence.

Megan Schroeder, Ph.D.
Megan J. Schroeder is Lead Pharmacologist within the Division of Individual Health Science/Office of Science at the U.S. Food and Drug Administration’s Center for Tobacco Products (CTP). She’s been with CTP since 2012. Her ongoing research interests include the clinical pharmacology of alternative tobacco products, menthol, and the impacts of polytobacco use on nicotine dependence. As a member of the Behavioral and Clinical Pharmacology Branch, Dr. Schroeder is responsible for the design, implementation, and oversight of contractual clinical studies, as well as reviewing tobacco product regulatory submissions. Megan received her Ph.D. in Pharmacology from Georgetown University in 2010 and completed a post-doctoral fellowship at the National Institutes of Health.

Stacey Sigmon, Ph.D.
Dr. Sigmon’s research on substance abuse has had two primary areas of focus. First, for two decades she has been investigating cigarette smoking and nicotine reinforcement among smokers with concurrent substance abuse disorders. This has included the development of a behavioral intervention to promote smoking abstinence among opioid-dependent smokers, in which across three sequential randomized trials has provided the strongest evidence to date that methadone- and buprenorphine-maintained adults can quit smoking. Dr. Sigmon is one of the Project PI’s for the Vermont Center on Behavior and Health P50 Tobacco Center of Regulatory Science center grant which investigates reduced-nicotine cigarettes in vulnerable smokers. Specifically, her project examines the effects of very low nicotine content cigarettes to assess their potential as a less addictive alternative to current commercial cigarettes in opioid-dependent smokers. Second, Dr. Sigmon has been conducting opioid behavioral pharmacology and treatment research for approximately 25 years. Recent examples include a randomized clinical trial demonstrating the efficacy of a buprenorphine taper + naltrexone treatment for opioid-dependent patients, as well as studies evaluating sustained-release formulations of buprenorphine which may permit maintenance treatment with less frequent administration. Finally, given the lengthy waitlists that often exist for opioid treatment, Dr. Sigmon has been developing and
evaluating a novel technology-aided interim buprenorphine dosing regimen for reducing illicit drug use and other risk behaviors during delays to opioid treatment.

Jennifer Tidey, Ph.D.
Dr. Tidey is Professor of Psychiatry and Human Behavior and a Professor of Behavioral and Social Sciences at Brown University’s Center for Alcohol and Addictions Studies, where she also is the Director of the Addictive Behaviors Laboratory and an Associate Director of the National Institute on Drug Abuse T32 training program. In addition, Dr. Tidey is an associate editor for the journals Nicotine and Tobacco Research and Tobacco Regulatory Science, and a member of the board of directors for the College on Problems of Drug Dependence. Trained as a behavioral pharmacologist at Tufts University, Dr. Tidey completed post-doctoral training at Harvard University and the University of Vermont before joining the Center for Alcohol and Addiction Studies at Brown University. The overall goals of her research are to identify mechanisms underlying the high rates of cigarette smoking in people with mental health conditions, and to develop effective smoking cessation treatments for these smokers. She currently conducts research in the high-impact area of tobacco regulatory science, the aim of which are to provide the U.S. Food and Drug Administration with the science it needs to make regulatory decisions about tobacco products, with the goal of improving public health. She actively mentors several pre-doctoral students, post-doctoral fellows, and junior faculty mentors in research involving cigarette smoking and use of other tobacco products in vulnerable populations.

Andrea Villanti, Ph.D., M.P.H.
Dr. Villanti is Research Associate Professor in the Department of Psychiatry, Vermont Center on Behavior and Health, at the University of Vermont. She also holds an adjunct faculty appointment at the Johns Hopkins Bloomberg School of Public Health. Dr. Villanti’s primary focus is on young adult tobacco use, including predictors and patterns of use and interventions to reduce tobacco use in young adults. She also has expertise in translational research to improve tobacco control policy and program decision-making, including tobacco regulatory science. She received her doctorate in social and behavioral sciences from the Johns Hopkins University and her master’s in public health degree from Columbia University.